

ALS2CR2 Antibody (C-term L289) Blocking Peptide
Synthetic peptide
Catalog # BP7110d**Specification**

ALS2CR2 Antibody (C-term L289) Blocking Peptide - Product InformationPrimary Accession [Q9C0K7](#)**ALS2CR2 Antibody (C-term L289) Blocking Peptide - Additional Information****Gene ID** 55437**Other Names**

STE20-related kinase adapter protein beta, STRAD beta, Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 2 protein, CALS-21, ILP-interacting protein, Pseudokinase ALS2CR2, STRADB, ALS2CR2, ILPIP

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP7110d](/products/AP7110d) was selected from the C-term region of human ALS2CR2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

ALS2CR2 Antibody (C-term L289) Blocking Peptide - Protein Information**Name** STRADB**Synonyms** ALS2CR2, ILPIP**Function**

Pseudokinase which, in complex with CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta), binds to and activates STK11/LKB1. Adopts a closed conformation typical of active protein kinases and binds STK11/LKB1 as a pseudosubstrate, promoting conformational change of STK11/LKB1 in an active conformation (By similarity).

Cellular Location

Nucleus. Cytoplasm

Tissue Location

Highly expressed in heart, skeletal muscle, testis, liver and colon.

ALS2CR2 Antibody (C-term L289) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

ALS2CR2 Antibody (C-term L289) Blocking Peptide - Images**ALS2CR2 Antibody (C-term L289) Blocking Peptide - Background**

ALS2CR2 potentiates the antiapoptotic activity of XIAP by enhancing XIAP-mediated activation of JNK1 (MAPK8) and other JNK family members, but not by modulating XIAP-mediated caspase inhibition. Expression of a catalytically inactive TAK1 (MAP3K7) mutant blocks the XIAP/ALS2CR2 activation of JNK1. In vivo coprecipitation experiments show that both ALS2CR2 and XIAP interact with TAK1 and TRAF6. It has been proposed that XIAP-mediated protection from apoptosis utilizes both a JNK1 activation pathway that involves ALS2CR2 and a caspase inhibition pathway that is independent of ALS2CR2.

ALS2CR2 Antibody (C-term L289) Blocking Peptide - References

Nishigaki, K., et al., J. Biol. Chem. 278(15):13520-13530 (2003). Sanna, M.G., et al., J. Biol. Chem. 277(34):30454-30462 (2002). Hadano, S., et al., Genomics 71(2):200-213 (2001).